ArticleCurrent colorectal cancer reports2019
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review.
Article in Current colorectal cancer reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Precision Medicine in Colorectal Cancer: Targeted Therapies and Biomarker Insights.Current cancer drug targets · 2026Review
- HIT101308137 and HIT104293658 nominate dual target chemotypes for PTPN1 and PTPN2 with preliminary selectivity in colorectal cancer cells.Frontiers in chemistry · 2026Article
- A prognostic lncRNA signature associated with ribonucleotide reductase predicts overall survival and immune landscape in hepatocellular carcinoma.Frontiers in cell and developmental biology · 2026Article
- BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.Molecular cancer therapeutics · 2025Article
- Article
- Precision treatment for human epidermal growth factor receptor 2-amplified advanced rectal cancer: A case report.World journal of gastrointestinal oncology · 2025Article
- SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.Nature communications · 2024Article
- Pancancer analysis of the prognostic and immunological role of FANCD2: a potential target for carcinogenesis and survival.BMC medical genomics · 2024Article
- Clinicopathological Profiles Associated with DiscordantCancers · 2023Article
- A review on emerging targeted therapies for the management of metastatic colorectal cancers.Medical oncology (Northwood, London, England) · 2023Review
- Current Targeted Therapy for Metastatic Colorectal Cancer.International journal of molecular sciences · 2023Review
- Targeted O-glycoproteomics for the development of diagnostic markers for advanced colorectal cancer.Frontiers in oncology · 2023Article
- Can dietary flavonoids be useful in the personalized treatment of colorectal cancer?World journal of gastrointestinal oncology · 2022Review
- Interrogating the interplay of angiogenesis and immunity in metastatic colorectal cancer.World journal of methodology · 2022Review
- Systematic analysis of the role of SLC52A2 in multiple human cancers.Cancer cell international · 2022Article
- Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.Oncoimmunology · 2022Article
- Article
- Survival in colon and rectal cancers in Finland and Sweden through 50 years.BMJ open gastroenterology · 2021Article
- Article
- MNK Inhibition SensitizesCancer discovery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewTreatment options for patients with metastatic colorectal cancer continue to advance as the therapeutic implications of the molecular subtypes of this disease are becoming better understood. DNA sequencing and mismatch repair assessment are now standard of care analyses for patients with metastatic colorectal cancer Thi review describes important aspects of the biology of the clinically relevant molecular subtypes of colorectal cancer based on the current standard of care testing. In addition, the clinical treatment strategies available now and potentially in the future for these colorectal cancer subtypes are discussed. RECENT
findingsCurrently for metastatic colorectal cancer, standard of care molecular testing is done for mutations in exons 2, 3, and 4 of SUMMARY: Altogether these data show promising treatment strategies for many of these well-known and emerging subtypes of mCRC. In addition, these also give better clinical prognostic and predictive information. We believe that as molecular testing expands
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.